Samsung Bioepis' latest approval gives it 5 biosimilar approvals in the European marketplace.
The European Commission (EC) has given marketing approval for the bevacizumab biosimilar Aybintio, by Samsung Bioepis.
The Incheon, Republic of Korea—based company said the EC has indicated the drug for the treatment of metastatic carcinoma of the colon or rectum, metastatic breast cancer, non–small cell lung cancer, advanced or metastatic renal cell cancer, epithelial ovarian, fallopian tube and primary peritoneal cancer, and cervical cancer. These encompass all approved indications for the reference product, Avastin.
The company noted the drug was approved based on analytical, pharmacokinetic, and clinical data, as well as pharmacology and toxicology data, all of which demonstrated that Aybintio and the reference product are highly similar with no clinically meaningful differences.
“Approval of Aybintio provides another treatment option for patients with certain types of cancers, enabling wider access to those in need,” said Christopher Hansung Ko, president and CEO of Samsung Bioepis, expressing pride in the drug authorization achievement.
Samsung Bioepis now has 5 biosimilars approved for use in Europe. These include Benepali (etanercept), Flixabi (infliximab), Ontruzant (trastuzumab), and Imraldi (adalimumab).
In June, Aybintio was recommended for approval by Europe's Committee for Medicinal Products for Human Use.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.